Trial Profile
A first-time-in-human single ascending dose trial of TRV250 for the treatment of acute migraine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs TRV 250 (Primary) ; TRV 250 (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man; Pharmacokinetics
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 16 Jul 2020 Results published in the CNS Drugs
- 12 Dec 2019 According to a Trevena Media Release, data from this study was presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), in Orlando, FL.